192 related articles for article (PubMed ID: 30048166)
1. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
3. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
Pelewicz K; Miśkiewicz P
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38310626
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
6. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
7. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
8. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
[TBL] [Abstract][Full Text] [Related]
9. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
10. Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy.
Walasik-Szemplińska D; Kamiński G; Sudoł-Szopińska I
Thyroid Res; 2019; 12():13. PubMed ID: 31890036
[TBL] [Abstract][Full Text] [Related]
11. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
12. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
[TBL] [Abstract][Full Text] [Related]
13. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
14. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
16. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
[TBL] [Abstract][Full Text] [Related]
17. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome.
Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P
J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161
[TBL] [Abstract][Full Text] [Related]
18. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
20. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
